tissues, but at tenfold lower levels than in prostate. The only prostate cancer cell line that expresses 1B10 is an androgen-sensitive cell line, LNCaP, suggesting that the gene might be androgen-regulated. Cloning of the full-length cDNA has so far resulted in 4.6 kb of the transcript. The 3′ end of the coding region is significantly homologous to a prostate-specific transmembrane protein, STEAP, but the rest of the sequence does not show homology to any known gene. Cloning of the 5′ end of the cDNA and functional studies are now in progress.
We are discovering new drug targets for cancer using a combination of genomic and functional assay technologies. As part of our discovery and validation process we use DNA microarrays to determine the patterns of gene expression in normal tissue, primary tumors and metastatic tumors across a cancer patient population. Tens of thousands of genes, including cancer genes discovered by highly sensitive gene profiling technology, are placed on our DNA microchips. Our DNA microarray technology is highly sensitive and reproducible, allowing us to assay laser capture microdissected material from human biopsy samples. We analyze differential gene expression patterns in the cancer patient population using new clustering approaches. These patterns are, in turn, analyzed against our database of gene expression profiles obtained from cell lines in which pathways have been manipulated, and pathways that are altered in patients are identified. We then further evaluate selected differentially expressed genes, along with their pathways, as potential targets for diagnostic and therapeutic approaches using functional analysis.
Ratner, Nancy
[12]
Gene expression analysis of NF1 mutant Schwann cells Larger numbers of genes were differentially expressed in Nf1 -/-TXF Schwann cells; some were sensitive to farnesyl transferase inhibitor. We report on the reproducibility of the data and confirm the RNA and protein levels for some identified genes. We have also begun an effort to share array data among laboratories studying neurofibromatosis as part of an international consortium. By applying these methods to NF1 model systems we hope to learn how neurofibromin serves as a tumor suppressor and to identify potential biomarkers and therapeutic targets for improved management of neurofibromatosis.
